Invention Grant
- Patent Title: Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
-
Application No.: US17856502Application Date: 2022-07-01
-
Publication No.: US12023315B2Publication Date: 2024-07-02
- Inventor: Kathleen Clarence-Smith
- Applicant: DAS-MG, Inc.
- Applicant Address: US MA Boston
- Assignee: Somerset Therapeutics, LLC
- Current Assignee: Somerset Therapeutics, LLC
- Current Assignee Address: US FL Hollywood
- Agency: Transformative Legal LLC
- Agent Len S. Smith; Julie E. Kurzrok
- Main IPC: A61K31/24
- IPC: A61K31/24 ; A61K31/5377 ; A61P21/04
Abstract:
The present invention describes the administration of an NK1 antagonist, in combination with neostigmine methylsulfate, intravenously, via subcutaneous infusion, or both intravenously and via subcutaneous infusion to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective neostigmine methylsulfate daily dose without the dose-limiting gastrointestinal adverse effects associated with neostigmine methylsulfate.
Public/Granted literature
Information query
